SCM
GILD icon

Smead Capital Management’s Gilead Sciences GILD Stock Holding History

Smead Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-696,561
Closed -$58.1M – 30
2016
Q2 		$58.1M Sell
696,561
-42,366
-6% -$3.76M 2.73% 21
2016
Q1 		$67.9M Sell
738,927
-67,071
-8% -$6.05M 2.93% 21
2015
Q4 		$67.4M Buy
805,998
+211,589
+36% +$22M 3.01% 19
2015
Q3 		$58.4M Buy
594,409
+134,185
+29% +$14.9M 3.11% 20
2015
Q2 		$53.9M Buy
460,224
+184,882
+67% +$20.2M 3.52% 13
2015
Q1 		$27M Buy
+275,342
New +$28M 1.99% 25

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Smead Capital Management's GILD Position: Q3 2016 in Review

Smead Capital Management sold out of Gilead Sciences (GILD) in Q3 2016, closing a stake of 696,561 shares — an estimated $58.1M sold.

Smead Capital Management first reported a position in GILD in Q1 2015 and held it in 6 quarters. The position peaked at $67.9M in Q1 2016. 1,561 funds tracked by Wall St. Rank hold GILD as of Q3 2016.

  • Smead Capital Management reported no remaining Gilead Sciences position as of Q3 2016 after selling out during the quarter.
  • Smead Capital Management sold 696,561 Gilead Sciences shares in Q3 2016, an estimated $58.1M.
  • Smead Capital Management first reported a position in Gilead Sciences in Q1 2015 and held it in 6 quarters.
  • Smead Capital Management's Gilead Sciences position peaked at $67.9M in Q1 2016.
  • 1,561 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2016.

Based on Smead Capital Management's 13F filing for Q3 2016, filed 7 Nov 2016.